First part of Belopenem formulation work is completed

Report this content

Double Bond Pharmaceutical has now completed the first part of formulation work for Belopenem project. This means that the first formulation that successfully combines the active substance meropenem and the Belogal platform is now ready and satisfies the analytical specifications for Belogal as a targeted formulation. The next step will start shortly and will aim to verify the targeted effect of the formulation in vivo.

“We are very satisfied with being able to keep the timeline and successfully complete the first step of the project, - Igor Lokot, CEO at Double Bond Pharmaceutical, comments. - ”Moreover, we have managed to improve Belogal platform while working with Belopenem formulation, which means that the product will have fewer excipients than we thought would be necessary and therefore will be easier and cheaper to manufacture and perform the toxicology on.”

Belopenem project is co-financed by Eureka and is an international collaboration between Double Bond Pharmaceutical together with Karolinska Institutet with SME from France.

More about Belopenem project: /mbpublicbinaryproxy/Main/12720/2576018/878966.pdf 

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 18 of March 2019. 

For more info, contact
Igor Lokot, CEO




Follow us on LinkedIn, Facebook and Twitter!

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. DBP has during the past year also started two subsidiaries, Drugsson AB for the distribution of fully developed human pharmaceutical and medical device products and dietary supplements in Scandinavia, and FarmPharma AB for the development of innovative veterinary products.



Documents & Links